The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology.Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Compare Kalyra Pharmaceuticals to its competitors by revenue, employee growth and other metrics at Craft.
{cd} Prior to joining Zentalis, he was a co-founder of Kalyra Pharmaceuticals and currently serves on the board of directors of Kalyra and as its Chief Scientific/Operations Officer. The popularity score combines profile views, clicks and the number of times the company appears in search results. See Kalyra Pharmaceuticals's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. Utilizing these enabling technology platforms, Aphios is developing enhanced therapeutics from a unique library of marine microorganisms and medicinal plants for heath maintenance as well as the prevention and treatment of certain cancers (prostate, breast and ovarian as well as nausea and emesis), infectious diseases (HIV, influenza and MRSA) and CNS disorders (Alzheimers Disease, pain, depression and addiction). Developer of medicines designed to address unmet needs in the area of pain management, anti-infectives and fibrosis. Arvinas is a pharmaceutical company focused on developing new small molecules ' known as PROTACs (PROteolysis TArgeting Chimeras) ' aimed at degrading disease-causing cellular proteins via proteolysis. Kalyra Pharmaceuticals VentureRadar profile. This organization has been operating for approximately 8 years. Kalyra Pharmaceuticals is a company developing non-opioid, non-NSAID (nonsteroidal anti-inflammatory drug) pain therapeutics. SuperFluids (SFS), the key and common component of Aphios patented technology platforms, are supercritical, critical or near-critical fluids with or without cosolvents which, when compressed, exhibit enhanced thermodynamic properties of penetration, selection, solvation and expansion. View company info, jobs, team members, culture, funding and more. It creates products that can be used alone and in combination with other analgesic classes to treat moderate to severe pain without the potential for addiction or abuse. Kalyra Pharmaceuticals General Information Description. He leads our R&D team in San Diego.
Amount: $999,830.00 | A New Class of Non-Opioid Analgesics for Use in Chronic Pain ManagementAmount: $306,161.00 | A New Treatment to Reduce ScarringAmount: $2,469,684.00 | A new class of non-opioid analgesics for use in chronic pain managementArvinas is a pharmaceutical company focused on developing new small molecules ' known as PROTACs (PROteolysis TArgeting Chimeras) ' aimed at degrading disease-causing cellular...Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA...FLAG Therapeutics develops cancer therapeutics using new classes of small molecules which have selective dual activity: antiangiogenesis and chemotherapeutic.DermaXon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic...Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry.